Cantor Fitzgerald Downgrades 4D Molecular Therapeutics (FDMT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts FDMT Hot Sheet
Price: $10.80 -8.86%
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Cantor Fitzgerald analyst Joshua Schimmer downgraded 4D Molecular Therapeutics (NASDAQ: FDMT) from Buy to Neutral.
For an analyst ratings summary and ratings history on 4D Molecular Therapeutics click here. For more ratings news on 4D Molecular Therapeutics click here.
Shares of 4D Molecular Therapeutics closed at $11.90 yesterday.
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
- Morgan Stanley Downgrades BE Semiconductor (BESI:NA) (BESIY) to Equalweight
- Guggenheim Downgrades Avalo Therapeutics Inc. (AVTX) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
